Nifty
Sensex
:
:
11844.10
39434.72
187.05 (1.60%)
623.33 (1.61%)

Pharmaceuticals & Drugs

Rating :
58/99  (View)

BSE: 532523 | NSE: BIOCON

534.60
24.00 (4.70%)
24-May-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  511.85
  •  535.95
  •  511.55
  •  510.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3107094
  •  16610.52
  •  718.00
  •  508.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 30,642.00
  • 33.85
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 31,583.20
  • 0.20%
  • 5.02

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 0.00%
  • 10.60%
  • FII
  • DII
  • Others
  • 1.16%
  • 3.21%
  • 24.36%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.87
  • 7.46
  • 7.20

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.87
  • 3.83
  • 1.55

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.10
  • -3.23
  • -12.76

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.05
  • 23.79
  • 44.64

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.69
  • 4.41
  • 5.55

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.38
  • 20.49
  • 26.33

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
1,528.80
1,169.50
30.72%
1,540.80
1,057.90
45.65%
1,321.00
968.60
36.38%
1,123.80
933.70
20.36%
Expenses
1,125.80
936.50
20.21%
1,160.10
836.20
38.73%
981.40
786.30
24.81%
886.00
741.60
19.47%
EBITDA
403.00
233.00
72.96%
380.70
221.70
71.72%
339.60
182.30
86.29%
237.80
192.10
23.79%
EBIDTM
26.36%
19.92%
24.71%
20.96%
25.71%
18.82%
21.16%
20.57%
Other Income
28.20
67.50
-58.22%
25.60
33.90
-24.48%
54.40
50.80
7.09%
68.80
54.00
27.41%
Interest
15.90
16.90
-5.92%
18.60
14.70
26.53%
18.80
13.80
36.23%
17.60
16.10
9.32%
Depreciation
119.80
95.30
25.71%
116.70
97.40
19.82%
112.20
93.60
19.87%
99.10
98.80
0.30%
PBT
295.50
188.30
56.93%
276.80
143.50
92.89%
451.80
125.70
259.43%
189.90
131.20
44.74%
Tax
40.90
40.70
0.49%
46.10
36.10
27.70%
73.20
42.50
72.24%
52.10
37.60
38.56%
PAT
254.60
147.60
72.49%
230.70
107.40
114.80%
378.60
83.20
355.05%
137.80
93.60
47.22%
PATM
16.65%
12.62%
14.97%
10.15%
28.66%
8.59%
12.26%
10.02%
EPS
3.56
2.17
64.06%
3.62
1.53
136.60%
5.91
1.15
413.91%
2.00
1.36
47.06%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
2,367.82
1,608.67
Net Sales Growth
33.53%
5.97%
16.24%
8.34%
7.39%
15.77%
19.11%
15.53%
-23.73%
47.19%
 
Cost Of Goods Sold
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
1,337.54
838.42
Gross Profit
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
1,030.27
770.25
GP Margin
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
59.17%
59.83%
43.51%
47.88%
Total Expenditure
4,153.30
3,294.30
2,911.60
2,579.60
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
1,896.33
1,285.31
Power & Fuel Cost
-
189.00
156.40
184.70
176.70
162.40
142.60
97.20
82.00
67.63
69.33
% Of Sales
-
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
4.66%
4.54%
2.86%
4.31%
Employee Cost
-
931.10
747.00
610.10
533.40
466.30
389.40
307.60
238.80
242.76
179.18
% Of Sales
-
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
14.74%
13.22%
10.25%
11.14%
Manufacturing Exp.
-
335.70
391.50
320.90
81.20
62.90
95.20
113.20
81.60
68.63
66.01
% Of Sales
-
8.14%
10.06%
9.59%
2.63%
2.19%
3.83%
5.43%
4.52%
2.90%
4.10%
General & Admin Exp.
-
56.80
21.70
42.60
165.70
131.80
122.20
93.20
82.40
79.09
56.15
% Of Sales
-
1.38%
0.56%
1.27%
5.36%
4.58%
4.92%
4.47%
4.56%
3.34%
3.49%
Selling & Distn. Exp.
-
98.20
107.40
100.80
108.70
118.90
99.60
89.40
62.40
56.49
47.67
% Of Sales
-
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
4.28%
3.46%
2.39%
2.96%
Miscellaneous Exp.
-
47.40
41.00
30.10
72.70
61.80
52.90
256.70
940.80
44.19
47.67
% Of Sales
-
1.15%
1.05%
0.90%
2.35%
2.15%
2.13%
12.30%
52.09%
1.87%
1.77%
EBITDA
1,361.10
829.10
979.50
767.80
695.80
687.10
539.00
277.20
-407.40
471.49
323.36
EBITDA Margin
24.68%
20.11%
25.17%
22.94%
22.52%
23.88%
21.69%
13.29%
-22.56%
19.91%
20.10%
Other Income
177.00
206.20
157.10
79.20
53.10
55.90
56.70
309.40
1,035.50
37.02
64.55
Interest
70.90
61.50
26.00
29.30
8.90
1.70
8.10
12.40
24.30
16.89
17.66
Depreciation
447.80
385.10
277.20
248.70
221.00
203.60
179.30
175.80
156.70
140.14
110.25
PBT
1,214.00
588.70
833.40
569.00
519.00
537.70
408.30
398.40
447.10
351.47
260.00
Tax
212.30
156.90
161.60
142.20
95.70
106.90
97.50
55.90
72.10
48.67
11.84
Tax Rate
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
13.85%
10.50%
PAT
1,001.70
351.10
595.80
528.70
497.40
413.80
508.90
341.60
367.50
293.25
93.84
PAT before Minority Interest
904.40
431.80
671.80
587.40
528.40
430.80
512.70
342.50
375.00
302.81
100.97
Minority Interest
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
-9.56
-7.13
PAT Margin
18.17%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
16.37%
20.35%
12.38%
5.83%
PAT Growth
131.98%
-41.07%
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
25.32%
212.50%
 
Unadjusted EPS
15.09
6.31
10.39
28.04
24.87
21.09
25.99
17.27
18.79
15.08
4.83

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
1,757.85
1,510.74
Share Capital
300.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
4,812.30
4,670.20
3,933.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
1,595.96
1,369.32
Non-Current Liabilities
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
564.44
570.54
Secured Loans
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
331.50
395.73
Unsecured Loans
2.80
3.90
11.40
11.40
25.80
40.00
60.50
65.80
182.11
128.18
Long Term Provisions
49.30
36.00
29.90
15.00
7.80
4.00
0.00
1.00
0.00
0.00
Current Liabilities
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
581.73
438.50
Trade Payables
1,005.30
739.70
609.80
429.30
347.20
345.50
347.80
296.50
230.86
208.55
Other Current Liabilities
870.10
698.20
527.10
706.20
612.30
313.10
269.20
375.90
260.05
148.42
Short Term Borrowings
130.30
97.20
394.90
261.00
243.50
84.80
187.30
247.40
0.00
0.00
Short Term Provisions
135.60
143.20
133.90
158.20
176.60
246.50
211.50
140.80
90.83
81.53
Total Liabilities
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55
Net Block
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
1,337.93
1,211.56
Gross Block
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
1,837.13
1,581.70
Accumulated Depreciation
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
499.20
370.14
Non Current Assets
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
1,460.60
1,422.68
Capital Work in Progress
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
75.52
172.02
Non Current Investment
63.80
188.80
26.80
0.00
64.50
64.50
64.20
60.90
47.16
39.10
Long Term Loans & Adv.
437.20
319.70
350.10
336.90
252.00
241.60
181.00
140.20
0.00
0.00
Other Non Current Assets
144.40
176.20
51.00
169.60
64.50
47.20
32.30
0.00
0.00
0.00
Current Assets
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
1,477.21
1,121.87
Current Investments
611.40
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
383.42
328.52
Inventories
722.50
635.30
542.40
452.70
376.60
398.40
378.30
413.70
371.64
319.18
Sundry Debtors
1,063.90
883.20
714.50
770.50
599.80
509.70
491.70
495.80
446.13
366.68
Cash & Bank
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
139.93
11.81
Other Current Assets
428.00
395.80
73.60
95.80
157.60
136.90
114.30
56.70
136.10
95.67
Short Term Loans & Adv.
54.70
24.10
227.10
75.80
81.80
81.40
37.10
20.20
120.28
95.05
Net Current Assets
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
895.48
683.37
Total Assets
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
662.10
640.00
526.40
210.70
560.70
471.20
564.10
798.50
443.81
95.10
PBT
610.00
849.70
1,227.40
624.10
537.70
610.20
395.20
447.10
351.47
104.36
Adjustment
355.70
204.40
-409.40
74.00
134.00
147.30
144.80
163.50
159.65
135.89
Changes in Working Capital
-106.50
-211.10
-44.80
-354.00
37.70
-192.30
98.00
269.20
-34.53
-128.21
Cash after chg. in Working capital
859.20
843.00
773.20
344.10
709.40
565.20
638.00
879.80
476.60
112.04
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-197.10
-203.00
-246.80
-133.40
-148.70
-94.00
-73.90
-81.30
-32.79
-16.94
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-684.00
-498.50
-954.00
-508.70
-938.10
-375.80
-359.50
-314.50
-226.07
-232.19
Net Fixed Assets
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
-55.73
-84.56
Net Investments
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
-71.95
130.57
Others
-195.40
-203.30
2,951.00
-779.30
-741.10
-200.00
-113.20
-112.27
-98.39
-278.20
Cash from Financing Activity
-239.70
-177.50
1,086.70
186.20
426.00
-8.60
-186.30
-274.60
-85.21
136.93
Net Cash Inflow / Outflow
-261.60
-36.00
659.10
-111.80
48.60
86.80
18.30
209.40
132.53
-0.16
Opening Cash & Equivalents
710.20
757.50
462.60
557.00
474.00
369.00
359.00
139.90
11.81
9.62
Closing Cash & Equivalent
449.00
710.20
1,127.00
462.60
557.00
474.00
369.00
359.00
143.10
11.81

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
85.19
79.49
67.22
53.86
48.42
43.18
36.31
32.49
28.25
24.47
ROA
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
11.05%
4.37%
ROE
8.74%
15.26%
16.17%
17.22%
15.68%
21.50%
16.59%
20.58%
19.14%
6.93%
ROCE
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
17.12%
6.92%
Fixed Asset Turnover
0.73
0.89
1.05
1.09
1.12
1.11
1.06
0.97
1.42
1.19
Receivable days
86.05
74.35
80.16
80.09
69.48
72.22
84.37
93.20
60.98
69.27
Inventory Days
60.00
54.81
53.71
48.47
48.54
56.01
67.67
77.71
51.83
55.14
Payable days
87.96
78.68
68.27
58.15
55.73
65.24
70.25
70.62
41.52
51.80
Cash Conversion Cycle
58.09
50.48
65.60
70.42
62.29
62.99
81.79
100.29
71.30
72.61
Total Debt/Equity
0.44
0.48
0.61
0.35
0.30
0.10
0.12
0.17
0.30
0.36
Interest Cover
10.57
33.05
25.90
71.12
317.29
76.33
33.13
19.40
21.81
7.39

News Update


  • Health Canada approves Biocon & Mylan's Ogivri
    23rd May 2019, 14:34 PM

    Ogivri is the first trastuzumab biosimilar approved in Canada

    Read More
  • Biocon, Mylan to present final data from HERITAGE study in Chicago
    16th May 2019, 12:49 PM

    The HERITAGE study compared Ogivri to the reference product, Herceptin, in patients with HER2+ metastatic breast cancer

    Read More
  • Biocon retains economic interest in global commercialization of Hulio in-licensed by Mylan
    8th May 2019, 11:27 AM

    Biocon is committed to enable patient access to affordable biosimilars

    Read More
  • Biocon reports 64% rise in Q4 consolidated net profit
    26th Apr 2019, 11:33 AM

    Total consolidated income of the company rose 25.87% at Rs 1,557.00 crore for quarter ended March 31, 2019

    Read More
  • Biocon - Quarterly Results
    25th Apr 2019, 19:12 PM

    Read More
  • Biocon to sell its business undertaking relating to drug substance
    3rd Apr 2019, 10:05 AM

    The Board of Directors of the company at their meeting held on April1, 2019, approved the same

    Read More
  • USFDA concludes inspection of Biocon's insulin drug substance manufacturing facility
    7th Mar 2019, 09:14 AM

    The inspection at the Bengaluru facility took place on February 25 - March 05, 2019

    Read More
  • USFDA concludes two pre approval inspections of Biocon's facilities in Bengaluru
    18th Feb 2019, 10:12 AM

    There were no observations and no form 483 was issued after the pre-approval inspection of Biocon's Oral Solid Dosage Facility conducted between February 11-15, 2019

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.